Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated by heavyweights…
Danish biotech Zealand Pharma is targeting the"next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly.
"Our focus is really what's needed in the 2030s, and it's really about establishing, you can say, the next-generation molecules that are not based on GLP-1s," Steensberg said.from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide.
"It's two very different human experiences," Steensberg said, comparing GLP-1s with amylin analogs."If you work on satiety, it will be a more pleasant experience. So once you get into it, you can stay long-term treatment." "If we can develop a molecule that is giving patients the weight loss they're looking for with a very benign tolerability profile, and we can also show risk reduction when it comes to cardiovascular health, I think we have all the reasons to believe it could become a first-line therapy," Steensberg told CNBC in the interview Thursday.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Cost Has Many Going Around Doctors to Get Weight-Loss MedsWegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days.
Read more »
Weight-Loss Drug Zepbound May Work Better in Women Than MenThe injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval.
Read more »
Women Taking Mounjaro And Zepbound Lose More Weight Than Men, New Study Suggests: What To KnowArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
Women Taking Mounjaro And Zepbound Lose More Weight Than Men, New Study Suggests: What To KnowArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
Zepbound In Vials: Tips For Safely Administering The New Weight Loss DrugThe FDA has raised concerns about potential dosing errors with weight loss drugs, particularly those in vial and syringe format. With the recent release of Zepbound vials at a lower cost compared to prefilled pens, it's important for patients to learn how to safely administer this new medication. Doctors offer tips and guidance on making the switch to self-administration.
Read more »
Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound, caught up in East Coast trade shutdownHigh demand for blockbuster weight-loss drugs such as Ozempic and Mounjaro is being tested by a ports strike hitting import hubs for Novo Nordisk and Eli Lilly.
Read more »